---
title: "HENLIUS's new indication drug registration application has been accepted"
description: "Fosun Pharma announced that its controlling subsidiary HENLIUS has received acceptance from the National Medical Products Administration for the drug registration application of Surufatinib Injection "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/269621083.md"
published_at: "2025-12-14T09:24:57.000Z"
---

# HENLIUS's new indication drug registration application has been accepted

> Fosun Pharma announced that its controlling subsidiary HENLIUS has received acceptance from the National Medical Products Administration for the drug registration application of Surufatinib Injection (trade name: Hansizhuang) for a new indication (i.e., in combination with platinum-based chemotherapy as neoadjuvant therapy and postoperative adjuvant treatment for patients with resectable gastric cancer who are PD-L1 positive) and has been included in the priority review process

Fosun Pharma (02196.HK) announced that its controlling subsidiary HENLIUS (02696.HK) has had its drug registration application for a new indication of Surufatinib Injection (trade name: Hansizhuang) accepted by the National Medical Products Administration. This new indication is for use in combination with platinum-based chemotherapy as neoadjuvant therapy and postoperative adjuvant therapy for patients with resectable gastric cancer who are PD-L1 positive. The application has also been included in the priority review process

### Related Stocks

- [02696.HK - HENLIUS](https://longbridge.com/en/quote/02696.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer | Shanghai Henlius Biotech Inc. has initiated a phase 1b/2 clinical trial for HLX43, an anti-PD-L1 antibody-drug conjugate | [Link](https://longbridge.com/en/news/275577160.md) |
| Shanghai Henlius Biotech Inc announces phase 3 trial success for Hansizhuang in gastric cancer | Shanghai Henlius Biotech Inc. announced the success of its phase 3 clinical trial for HANSIZHUANG (serplulimab injection | [Link](https://longbridge.com/en/news/260398601.md) |
| Towa Pharmaceutical (TSE:4553) Margin Firmness Reinforces Defensive Earnings Narrative In Q3 2026 | Towa Pharmaceutical (TSE:4553) reported solid Q3 2026 results with revenue of ¥73.6b and net income of ¥8.9b, reflecting | [Link](https://longbridge.com/en/news/275991027.md) |
| Hangzhou Jiuyuan Gene Engineering IND Application for JY54 Injection Accepted by CDE | Hangzhou Jiuyuan Gene Engineering Co. Ltd. has announced that its IND application for JY54 Injection has been accepted b | [Link](https://longbridge.com/en/news/275289286.md) |
| Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application | Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application | [Link](https://longbridge.com/en/news/275893661.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.